Drawing for TITRADOSE

USPTO serial 72377759

TITRADOSE

Reviewed by CopyMark Law Group

Reg. 0943111Status 900
Filing date
Status date
Registration date
Sep 19, 1972
Examiner
โ€”
Law office
FILE REPOSITORY (FRANCONIA)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with TITRADOSE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

GLENDA DA FONSECA

GLENDA DA FONSECA AMERICAN HOME PRODUCTS CORPORATION685 3RD AVENEW YORK, NY 10017-4049UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
018SPECIAL FORM OF TABLETS TO BE USED FOR PHARMACEUTICAL PRODUCTS FOR TITRATION OF DOSAGEEXPIREDNov 19, 1970

Related trademarks

CopyMark links this record to cited ยง2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 21, 2003CAEXCANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9โ€”
Jul 8, 1992RNL1REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active.
Mar 26, 19929.AFREGISTERED - SEC. 9 FILED/CHECK RECORD FOR SEC. 8โ€”
Nov 7, 19778.OKREGISTERED - SEC. 8 (6-YR) ACCEPTEDThe USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline.

Frequently asked questions

Related guidance